Published work

For an updated publication list, please see: weblink

Original Peer-Reviewed Publications
  • Stronczek C, Lange S, Bullard B, Wolniak S, Börgeson E, Mayans O, Fleming JR. The N2A region of titin has a unique structural configuration. Journal of General Physiology. 2021. 153(7):e202012766.
  • Börgeson E*, Sotak M, Kraft J, Bagunu G, Biörserud C, Lange S. Challenges in PhD education due to COVID-19 - disrupted supervision or business as usual: a cross-sectional survey of Swedish biomedical sciences graduate students. BMC Medical Education. 2021. 21(1):294.
  • Zhou T, Fleming JR, Lange S, Hessel A, Bogomolovas J, Stronczek C, Grundei D, Ghassemian M, Biju A, Börgeson E, Bullard B, Linke W, Chen J, Kovermann M, Mayans O. Molecular characterization of titin N2A and its complexation of CARP suggests a titin/actin cross-linking mechanism. Journal of Molecular Biology. 2021. 166901.
  • Fleming JR, Rani A, Kraft J, Zenker S, Börgeson E*, Lange S. Exploring Obscurin and SPEG Kinase Biology. Journal of Clinical Medicine. 2021. 10(5):984.
  • Soták M, Casselbrant A, Rath E, Zietek T, Strömstedt M, Adingupu DD, Karlsson D, Fredin MF, Ergang P, Pácha J, Batorsky A, Alpers CE, Börgeson E, Hansen PBL, Ericsson A, Granqvist AB, Wallenius V, Fändriks L, Unwin RJ. Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity. Life Sciences. 2020. 118974.
  • Rajan MR, Sotak M, Barrenas F, Shen T, Borkowski K, Ashton NJ, Biörserud C, Lindahl TL, Ramstrom S, Scholl M, Lindahl P, Fiehn O, Newman JW, Perkins R, Wallenius V, Lange S, Börgeson E*. Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Scientific Reports. 2019. 15385.
  • Lange S, Banerjee I, Carrion K, Serrano R, Habich L, Kameny R, Lengenfelder L, Dalton N, Meili R, Börgeson E, Peterson K, Ricci M, Lincoln J, Ghassemian M, Fineman J, Del Álamo JC, Nigam V. miR-486 is modulated by stretch and increases ventricular growth. JCI Insight. 2019. 4(19).
  • Hernandez-Carretero A, Weber N, La Frano MR, Ying W, Lantero Rodriguez J, Sears DD, Wallenius V, Börgeson E, Newman JW, Osborn O. Obesity-induced changes in lipid mediators persist after weight loss. International Journal of Obesity (London). 2018. 728-736.
  • Börgeson E*, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K. AICAR ameliorates high fat diet associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia. 2017. 60(4):729739.
  • Zhong L, Ding Y, Bandyopadhyay G, Waaler J, Börgeson E, Smith S, Zhang M, Phillips SA, Mahooti S, Mahata SK, Shao J, Krauss S, Chi NW. The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice. Diabetologia. 2016. 59(3):582-91.
  • Börgeson E*, Johnsson A, Lee Y.S., Till A, Syed H, Ali-Shah, Guiry P, Dalli D, Colas R, Serhan CN, Godson C, Sharma K. Lipoxin A4 attenuates obesity-induced adipose inflammation, liver and kidney disease. Cell Metabolism. 2015. 22(1):125-37
  • Corcoran JB, McCarthy S, Griffin B, Gaffney A, Bhreathnach U, Börgeson E, Hickey FB, Docherty NG, Higgins DF, Furlong F, Martin F, Godson C, Murphy M. IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses. Biochimica Biophys Acta. 2013. 1833(8):1969-78.
  • Brennan EP, Nolan KA, Börgeson E, Gough OS, McEvoy CM, Docherty NG, Higgins DF, Murphy M, Sadlier DM, Ali-Shah ST, Guiry PJ, Savage DA, Maxwell AP, Martin F, Godson C. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. Journal of the American Society of Nephrology. 2013. 24(4):627-37.
  • Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. Lipoxin A4 attenuates adipose inflammation. FASEB Journal. 2012. 26(10):4287-94.
  • Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB Journal. 2011. 25(9):2967-79.
  • Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T. Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. Infection and Immunity. 2011. 79(4):1489-97

Peer-Reviewed Review Articles
  • Kraft JD, Blomgran R, Lundgaard I, Quiding-Järbrink M, Bromberg JS, Börgeson E*. Specialized Pro-Resolving Mediators and the Lymphatic System. International Journal of Molecular Science. 2021. 22(5):2750.
  • Börgeson E*. The role of lipoxins in cardiometabolic physiology and disease. Cardiovascular Endocrinology Journal. 2015. 5(1):4-13.
  • Börgeson E, Sharma K. Obesity, immunomodulation and chronic kidney disease. Current Opinions in Pharmacology. 2013. 13(4):618-24.
  • Börgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Frontiers in Immunology. 2012. 3:318.
  • Börgeson E, Godson C. Molecular circuits of resolution in renal disease. Scientific World Journal. 2010. 10:1370-85.
Börgeson | Lab
University of Gothenburg, Sweden
Web Design:   Madison Clark
     Photos: Madison Clark & Johan Wingborg (GU)